Aptiom is struggling. Latuda is facing stiff competition and short patent life. Brovana patent ends soon. Lonhala Magnair is failing and price point is 3x above the market value price point. Run Forrest Run.
Brovana is first part of 2021. Those of you that were around when they had Lunesta & Xopenex will remember how they handled those products going generic. They cut the sales team efforts over a year out. To make as much profit as they can. I remember hearing from marketing that market share doesn’t drop off at a certain point of a drug’s life.
The pipeline is good for CNS, maybe??? The last few products to come out having been approved. The new submission looks good...but do some research on all the companies that are racing towards the same indications with similarly MOA products. It’s going to be a very tough grind and niched sell with all these drugs.
The mileage logs are easy. About 3 miles to the grocery and liquor stores where I live. Round trip=6 miles.
